Antibacterial resistance worldwide: causes, challenges and responses

By S. Levy, B. Marshall. Nature Medicine, 2004

4,046 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Infectious Diseases, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/24aa7c96b54a44ca5d6877dd435b5ce62177df17

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. A. Alanis
2. Kim Lewis
3. Gerard D. Wright
4. C. Seiler
5. Thomas U. Berendonk
6. S. Levy
7. D. Larsson
8. K. Kümmerer

In Infectious Diseases

1. A. Alanis
2. Kim Lewis
3. Gerard D. Wright
4. S. Levy
5. A. Peschel
6. D. Larsson
7. Nicholas Ashbolt
8. B. Marshall

In Molecular Medicine

1. A. Alanis
2. Kim Lewis
3. Gerard D. Wright
4. E. Dassa
5. C. Orelle
6. D. Larsson
7. C. Seiler
8. Thomas U. Berendonk

Citations in the corpus

• Human Health Risk Assessment (HHRA) for Environmental Development and Transfer of Antibiotic Resistance (2013, background): “Because it seems inevitable that ARB will eventually develop against any anti biotic (Levy and Marshall 2004), the key manage­ ment aim seems to be to delay and confine such a development as much as possible.”
• Food Animals and Antimicrobials: Impacts on Human Health (2011, background): “An ecological imbalance results—one that favors emergence and propagation of large numbers of resistance genes (113).”
• Emerging contaminants: A One Health perspective (2024, positive): “250,251 Thus, anthropogenic activities could increase the emergence of ARBs, their resistance genes, and their dissemination between the human, animal, and environmental compartments, aggravating the existing antibiotic resistance crisis.”
• Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance (2012, background): “tance to antimicrobials is lost at a fairly slow pace (121).”
• Evolutionary paths to antibiotic resistance under dynamically sustained drug stress (2011, background): “Antibiotic resistance is a growing global public health concer”
• The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. (2006, neutral): “Also considered were the inconvenience of prolonged therapies, the potential impact of the indiscriminate use of antibiotics on the development of antibiotic resistance in the community, and the economic costs [255].”
• The biology and future prospects of antivirulence therapies (2008, background): “Moreover, as most bacterial strains are becoming resistant to multiple antibiotics, including vancomycin (the current drug of choice for the treatment of MRSA), there is an urgent need for antibiotics that have new modes of action on therapeutic target”